{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT03485547","nct_id":"NCT03485547","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03485547. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"* Venetoclax is administered on a daily basis orally.\n* The investigators will use a modified 3+3 with a de-escalation dose level design to establish the appropriate and tolerable dose of venetoclax.","label":"Venetoclax","type":"EXPERIMENTAL"}],"collaborators":["AbbVie"],"completion_date":{"date":"2025-04-16","type":"ACTUAL"},"conditions":["Blastic Plasmacytoid Dendritic Cell Neoplasm"],"enrollment":{"count":5,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Venetoclax","otherNames":["Venclexta"],"type":"DRUG"}],"last_update":"2026-02-02","lead_sponsor":"Dana-Farber Cancer Institute","official_title":"Phase 1 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2022-01-10","type":"ACTUAL"},"primary_outcomes":[{"measure":"Dose Limiting Toxicity","timeFrame":"2 years"}],"references":[{"citation":"Wang SY, Thomassen K, Kurch L, Opitz S, Franke GN, Bach E, Platzbecker U, Kayser S. Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2021 Jul;21(7):e579-e582. doi: 10.1016/j.clml.2021.02.008. Epub 2021 Mar 2. No abstract available.","pmid":"33795208","type":"DERIVED"}],"start_date":{"date":"2018-08-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","url":"https://clinicaltrials.gov/study/NCT03485547"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03485547"}